A phase Ib trial of pembrolizumab plus paclitaxel or flat-dose capecitabine in 1st/2nd line metastatic triple-negative breast cancer
David B. Page(Providence Portland Medical Center), Heather L. McArthur(Southwestern Medical Center)
Cited by 7
Related Papers
Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k
Current Landscape of Immunotherapy in Breast Cancer
|JAMA Oncology|2019|409
Two may be better than one: PD-1/PD-L1 blockade combination approaches in metastatic breast cancer
|npj Breast Cancer|2019|86
Changes in T-cell subsets and clonal repertoire during chemoimmunotherapy with pembrolizumab and paclitaxel or capecitabine for metastatic triple-negative breast cancer
|Journal for ImmunoTherapy of Cancer|2022|18